Price T Rowe Associates Inc Curis Inc Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $15,614 - $316,711	21,100 Added 16.68%	147,600 $104,000
Q2 2022 Aug 15, 2022	BUY	$0.71 - $2.43 $51,994 - $177,953	73,232 Added 137.48%	126,500 $125,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $21,494 - $47,734	9,305 Added 21.17%	53,268 $127,000
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $30,491 - $55,432	-6,852 Reduced 13.48%	43,963 $209,000
Q3 2021 Nov 15, 2021	SELL	$6.94 - $8.85 $21,514 - $27,435	-3,100 Reduced 5.75%	50,815 $398,000
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $301,836 - $659,179	40,515 Added 302.35%	53,915 $435,000
Q1 2021 May 17, 2021	SELL	$8.78 - $12.8 $20,194 - $29,440	-2,300 Reduced 14.65%	13,400 $152,000
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $16,956 - $128,739	15,700 New	15,700 $129,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.